Pfizer launches 2 clinical trials in China for two triple therapy drugs to treat atopic dermatitis

On July 23, the Chinese Clinical Trial Registry and Information Disclosure Platform showed that Pfizer has registered a Phase II clinical trial in China to evaluate the efficacy and safety of PF-07275315 and PF-07264660 in adult subjects with moderate to severe atopic dermatitis. PF-07275315 is a triple-specific antibody targeting IL-4×IL-13×TSLP, while PF-07264660 is a triple-specific antibody targeting IL-4×IL-13×IL-33. Atopic dermatitis (AD) is a common chronic, recurrent, inflammatory skin disease. IL-4 and IL-13 are important cytokines in the pathogenesis of AD, playing a key role in the development of AD. Pfizer plans to develop these two triple antibody drugs for the treatment of atopic dermatitis indications. Overseas, these two investigational drugs have already entered Phase 2 clinical trials